Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Autores
CARVALHO, Vinicius Jardim
LOUREIRO, Rafael Maffei
BRANTIS-DE-CARVALHO, Carlos Eduardo
Citação
JOURNAL FOR IMMUNOTHERAPY OF CANCER, v.9, n.7, article ID e003044, 2p, 2021
Resumo
A commentary on the original research article: 'Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers'. Of note, the predictor selection process, the cross-validation method, along with the lack of final testing of the developed model with a separated data set may mask overfitting, overestimating performance metrics.
Palavras-chave
immunotherapy
Referências
- Burkov A, 2019, HUNDRED PAGE MACHINE
- Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
- Chen T., 2016, KDD16 P 22 ACM, DOI 10.1145/2939672.2939785
- Colen RR, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001752
- Gronning B., 2001, STAT MED, V20, P1888
- He ZY, 2010, COMPUT BIOL CHEM, V34, P215, DOI 10.1016/j.compbiolchem.2010.07.002
- Jain A, 1997, IEEE T PATTERN ANAL, V19, P153, DOI 10.1109/34.574797
- Koza J.R., 1996, ART INT DES 96, P151, DOI 10.1007/978-94-009-0279-4_9
- Rao RB., 2008, P 2008 SIAM INT C DA, P588
- Varoquaux G, 2017, NEUROIMAGE, V145, P166, DOI 10.1016/j.neuroimage.2016.10.038